What is William Blair's Forecast for OVID FY2025 Earnings?

Key Points

• William Blair has revised its FY2025 earnings estimate for Ovid Therapeutics to ($0.50) per share, an improvement from the previous estimate of ($0.58).
• Ovid Therapeutics reported a quarterly earnings of ($0.06) EPS, surpassing analysts' expectations of ($0.16) EPS, and achieved a revenue of $6.27 million compared to a consensus estimate of just $0.09 million.
• The stock currently holds a consensus rating of "Buy" with a target price of $3.10, and 72.24% of the company’s shares are held by institutional investors.

Ovid Therapeutics (NASDAQ:OVID - Free Report) - Research analysts at William Blair raised their FY2025 earnings per share (EPS) estimates for Ovid Therapeutics in a report issued on Wednesday, August 13th. William Blair analyst M. Minter now forecasts that the company will post earnings of ($0.50) per share for the year, up from their prior estimate of ($0.58). William Blair has a "Strong-Buy" rating on the stock. The consensus estimate for Ovid Therapeutics' current full-year earnings is ($0.40) per share. William Blair also issued estimates for Ovid Therapeutics' Q1 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.18) EPS, Q4 2026 earnings at ($0.20) EPS, FY2026 earnings at ($0.72) EPS, FY2027 earnings at ($1.01) EPS, FY2028 earnings at ($1.13) EPS and FY2029 earnings at ($1.23) EPS.

Ovid Therapeutics (NASDAQ:OVID - Get Free Report) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.10. The company had revenue of $6.27 million for the quarter, compared to analyst estimates of $0.09 million. Ovid Therapeutics had a negative return on equity of 58.87% and a negative net margin of 574.44%.

Several other brokerages have also commented on OVID. B. Riley reissued a "buy" rating and issued a $3.00 price target on shares of Ovid Therapeutics in a report on Friday, August 8th. HC Wainwright decreased their target price on Ovid Therapeutics from $2.00 to $1.50 and set a "buy" rating on the stock in a research report on Tuesday, May 27th. Finally, Wall Street Zen upgraded Ovid Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 16th. One analyst has rated the stock with a Strong Buy rating and five have issued a Buy rating to the company's stock. According to MarketBeat.com, Ovid Therapeutics has a consensus rating of "Buy" and an average price target of $3.10.

Ovid Therapeutics Price Performance

NASDAQ OVID traded up $0.0730 on Monday, hitting $1.03. The company had a trading volume of 1,199,135 shares, compared to its average volume of 1,525,876. The company has a market capitalization of $73.24 million, a PE ratio of -1.94 and a beta of 0.20. The company's fifty day moving average price is $0.52 and its 200-day moving average price is $0.44. The company has a debt-to-equity ratio of 0.23, a current ratio of 4.72 and a quick ratio of 4.72. Ovid Therapeutics has a 12-month low of $0.2425 and a 12-month high of $1.47.

Institutional Investors Weigh In On Ovid Therapeutics

A number of large investors have recently made changes to their positions in OVID. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Ovid Therapeutics in the fourth quarter valued at approximately $934,000. Affinity Asset Advisors LLC purchased a new stake in shares of Ovid Therapeutics in the first quarter valued at approximately $208,000. Rosalind Advisors Inc. purchased a new stake in shares of Ovid Therapeutics in the second quarter valued at approximately $165,000. Assenagon Asset Management S.A. grew its position in shares of Ovid Therapeutics by 699.9% in the first quarter. Assenagon Asset Management S.A. now owns 560,830 shares of the company's stock valued at $175,000 after purchasing an additional 490,716 shares in the last quarter. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Ovid Therapeutics by 50.2% in the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 943,416 shares of the company's stock valued at $881,000 after purchasing an additional 315,126 shares in the last quarter. 72.24% of the stock is currently owned by hedge funds and other institutional investors.

About Ovid Therapeutics

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.